Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

What is the purpose of this trial?

This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade ovarian cancer. Subjects should have received at least 2 prior lines of platinum-based chemotherapy.


Participation Guidelines

Ages: 18 - 130 years

Gender: Female only


Astra Zeneca, L.P.

Start Date: 11/06/2017

End Date: 12/31/2019

Last Updated: 02/22/2018

Study HIC#: 2000020446

Get Involved

For more information about this study, contact:
Michele K Hill
+1 203-737-7660
michele.montagna@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image